系统综述与Meta分析:门静脉再通与经颈静脉肝内门体分流术治疗门静脉血栓
该系统综述与Meta分析检索PubMed、ISI、Scopus和Embase截至2017年10月的英文研究,纳入13项研究共399例良性门静脉血栓接受血管内治疗的患者(92%为肝硬化)。结果显示经颈静脉肝内门体分流术技术可行率95%,12个月门静脉再通率79%、分流道通畅率84%、总生存率89%;海绵样变为技术失败的主要决定因素,联合导管导向溶栓与严重并发症风险升高相关。
要点
- 经颈静脉肝内门体分流术治疗门静脉血栓技术可行率95%(95%CI:89%-98%),海绵样变是技术失败的主要决定因素
- 12个月门静脉再通率79%、分流道通畅率84%、总生存率89%
- 联合导管导向溶栓较单纯经颈静脉肝内门体分流术或加血栓切除术并发症更多(17.6% vs 3.3%)
核心结论
- 作者认为经颈静脉肝内门体分流术用于门静脉血栓再通高度可行、有效且安全;海绵样变是技术失败的主要决定因素;联合导管导向溶栓与严重并发症风险升高相关。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、ISI、Scopus和Embase截至2017年10月的英文研究,纳入13项研究共399例良性门静脉血栓接受血管内治疗的患者,采用随机效应模型进行汇总分析。
- 纳入患者中92%为肝硬化;门静脉血栓完全性46%、慢性87%、海绵样变17%、肠系膜上静脉受累55%。
- 采用预设数据字段与质量指标独立提取文献,异质性通过Cochran Q、I2统计量、亚组分析和Meta回归评估。
主要发现
- 经颈静脉肝内门体分流术技术可行率95%(95%CI:89%-98%),异质性I2=57%(P<0.001),由海绵样变解释。
- 严重并发症发生率10%(95%CI:6.0%-18.0%;I2=52%,P=0.55)。
- 联合导管导向溶栓较单纯经颈静脉肝内门体分流术或加血栓切除术并发症更多(17.6% vs 3.3%)。
- 12个月门静脉再通率79%(95%CI:67%-88%;I2=78%,P<0.01);12个月分流道通畅率84%(95%CI:76%-90%;I2=62%,P<0.01)。
- 总12个月生存率89%,无异质性。
关键数值与推荐
- 经颈静脉肝内门体分流术技术可行率95%(95%CI:89%-98%)。
- 12个月门静脉再通率79%(95%CI:67%-88%);12个月分流道通畅率84%(95%CI:76%-90%);总12个月生存率89%。
- 严重并发症发生率10%(95%CI:6.0%-18.0%)。
- 联合导管导向溶栓较单纯经颈静脉肝内门体分流术或加血栓切除术并发症更多(17.6% vs 3.3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 经颈静脉肝内门体分流术技术可行率存在异质性(I2=57%,P<0.001),由海绵样变解释。
- 12个月门静脉再通率存在异质性(I2=78%,P<0.01)。
- 12个月分流道通畅率存在异质性(I2=62%,P<0.01)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transjugular intrahepatic portosystemic shunt has been increasingly used in patients with portal vein thrombosis to obtain patency, but evidenced-based decisions are challenging. AIM: To evaluate published data on efficacy and safety of endovascular therapy in portal vein thrombosis. METHODS: Systematic search of PubMed, ISI, Scopus, and Embase for studies (in English, until October 2017) reporting feasibility, safety, 12-month portal vein recanalisation, transjugular intrahepatic portosystemic shunt patency, and survival in patients with benign portal vein thrombosis undergoing endovascular treatment. An independent extraction of articles using predefined data fields and quality indicators was used; pooled analyses based on random-effects models; heterogeneity assessment by Cochran's Q, I2 statistic, subgroup analyses, and meta-regression. RESULTS: Thirteen studies including 399 patients (92% cirrhosis; portal vein thrombosis: complete 46%, chronic 87%, cavernous transformation 17%, superior mesenteric vein involvement 55%) were included. Transjugular intrahepatic portosystemic shunt was technically feasible in 95% (95% CI: 89%-98%) with heterogeneity (I2 = 57%, P < 0.001) explained by cavernous transformation. Major complications occurred in 10% (95% CI: 6.0%-18.0%; I2 = 52%, P = 0.55). Additional catheter-directed thrombolysis was associated with more complications compared to transjugular intrahepatic portosystemic shunt alone or plus thrombectomy (17.6% vs 3.3%). Twelve-month portal vein recanalisation was 79% (95% CI: 67%-88%; I2 = 78%, P < 0.01). Shunt patency at 12 months was 84% (95% CI: 76%-90%; I2 = 62%, P < 0.01). Overall 12-month survival rate was 89%, with no heterogeneity. CONCLUSIONS: Transjugular intrahepatic portosystemic shunt for portal vein thrombosis recanalisation was highly feasible, effective, and safe. Cavernous transformation was the main determinant of technical failure. Additional catheter-directed thrombolysis was associated with higher risk of severe complications.
引用
- Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther. 2018. PMID: 30450634. doi:10.1111/apt.15044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。